Genfit S.A. (EPA:GNFT)
France · Delayed Price · Currency is EUR 9.10
-0.34 (-3.60%)
Oct 2, 2026, 5:35 PM CET
Genfit Earnings Call Transcripts
Fiscal Year 2026
-
The event highlighted the urgent need for scalable, accurate MASH diagnostics as new therapies shift the market focus to patient identification and monitoring. NIS2+ is validated as a superior, non-invasive test, with strong clinical and commercial prospects, supported by pharma partnerships and a robust roadmap to global adoption.